AstraZeneca reveals new safety data for naloxegol in OIC

15 October 2013

AstraZeneca (LSE: AZN) has released results of a Phase III long-term safety and tolerability study of the once-daily 25mg dose of naloxegol, in patients with non-cancer pain and opioid-induced constipation (OIC) at the American College of Gastroenterology (ACG) 2013 Annual Scientific Meeting in San Diego, California.

Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA), which has been studied in OIC in adult patients with chronic non-cancer pain, a common condition caused by prescription opioid pain medicines.

The Phase III study, KODIAC-08 (n=844), was a 52-week, long-term safety trial of naloxegol (n=534) versus usual care (n=270) in patients with non-cancer related pain and OIC. Usual care was defined as the investigator’s choice of an existing laxative treatment regimen for OIC.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK